Palbociclib
- Generic Name
- Palbociclib
- Brand Names
- Ibrance
- Drug Type
- Small Molecule
- Chemical Formula
- C24H29N7O2
- CAS Number
- 571190-30-2
- Unique Ingredient Identifier
- G9ZF61LE7G
- Background
Palbociclib is a piperazine pyridopyrimidine that acts in the cell cycle machinery. It is a second generation cyclin-dependent kinase inhibitor selected from a group of pyridopyrimidine compounds due to its favorable physical and pharmaceutical properties.
...
- Indication
Palbociclib is indicated in combination with letrozole as initial endocrine-based therapy for the treatment of human epidermal growth factor receptor type 2 (HER2)-negative and hormone receptor(HR)-positive tumors in adult patients with advanced/metastatic breast cancer. It is as well approved in combination with fulvestrant in patients with disease progress...
- Associated Conditions
- Advanced Breast Cancer, Metastatic Breast Cancer, Refractory, advanced Breast cancer, Refractory, metastatic Breast cancer
- Associated Therapies
- -
Avelumab, Palbociclib and Axitinib in Advanced RCC
- Conditions
- Interventions
- First Posted Date
- 2022-01-04
- Last Posted Date
- 2023-09-07
- Lead Sponsor
- Bradley A. McGregor, MD
- Registration Number
- NCT05176288
Description of Treatment Patterns and Description and Comparison of Healthcare Resource Utilization and Costs of Women With Metastatic HR+/HER2- Breast Cancer Treated With CDK4/6 Inhibitors
- Conditions
- Interventions
- First Posted Date
- 2021-12-10
- Last Posted Date
- 2021-12-21
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 4320
- Registration Number
- NCT05153135
- Locations
- 🇺🇸
Novartis Investigative Site, East Hanover, New Jersey, United States
A Real-world Analysis of Concomitant Medication Use Among Metastatic Breast Cancer Patients Treated With CDK4/6 Inhibitors
- Conditions
- Interventions
- First Posted Date
- 2021-12-02
- Last Posted Date
- 2021-12-16
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 4650
- Registration Number
- NCT05141240
- Locations
- 🇺🇸
Novartis Investigational site, East Hanover, New Jersey, United States
Study Of Real-World Evidence In Patients Treated With Palbociclib During a 2.5 Years Follow-Up Period
- Conditions
- First Posted Date
- 2021-11-26
- Last Posted Date
- 2023-05-17
- Target Recruit Count
- 650
- Registration Number
- NCT05135104
- Locations
- 🇷🇴
Asociatia Oncohelp - Centrul de Oncologie Oncohelp, Timisoara, Timiș, Romania
🇷🇴Spitalul Clinic Județean de Urgență Cluj-Napoca, Cluj-Napoca, Romania
🇷🇴Institutul Oncologic "Prof. Dr I. Chiricuta", Cluj-Napoca, Romania
Neoadjuvant With Trastuzumab, Pyrotinib Plus Palbociclib and Fulvestrant in HER2-positive, ER-positive Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-10-13
- Last Posted Date
- 2021-10-13
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 37
- Registration Number
- NCT05076695
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Hospital, Shanghai, Shanghai, China
Cyclin dEpendent Kinase in tRiple nEGatIVe brEast canceR - a "Window of Opportunity" Study
- Conditions
- Interventions
- First Posted Date
- 2021-10-05
- Last Posted Date
- 2021-10-05
- Lead Sponsor
- Medical University of Gdansk
- Target Recruit Count
- 126
- Registration Number
- NCT05067530
- Locations
- 🇵🇱
Wielkopolskie Centrum Onkologii im. Marii Skłodowskiej-Curie, Oddział Onkologii Klinicznej i Immunoonkologii z Pododdziałem Dziennym, Poznań, Wielkopolskie, Poland
🇵🇱Dolnośląskie Centrum Onkologii we Wrocławiu, Oddział Onkologii Klinicznej/Chemioterapii, Poradnia Chemioterapii; Leczenie Nowotworów Piersi, Wrocław, Dolnośląskie, Poland
🇵🇱SP ZOZ Opolskie Centrum Onkologii im. Prof. Tadeusza Koszarowskiego, Opole, Opolskie, Poland
A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies
- Conditions
- Interventions
- First Posted Date
- 2021-09-09
- Last Posted Date
- 2024-03-04
- Lead Sponsor
- Erasca, Inc.
- Target Recruit Count
- 102
- Registration Number
- NCT05039177
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Virginia Cancer Specialists, Fairfax, Virginia, United States
🇺🇸University of Washington - Seattle Cancer Care Alliance, Seattle, Washington, United States
Palbociclib in Combination With Chemotherapy in Pediatric Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (RELPALL2)
- First Posted Date
- 2021-08-09
- Last Posted Date
- 2024-04-16
- Lead Sponsor
- Tanja Andrea Gruber
- Target Recruit Count
- 22
- Registration Number
- NCT04996160
- Locations
- 🇺🇸
Lucile Packard Children's Hospital Stanford, Stanford, California, United States
Prediction of 18F-FES-PET/CT Parameters on Palbociclib Combined With ET
- First Posted Date
- 2021-08-05
- Last Posted Date
- 2022-05-19
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 50
- Registration Number
- NCT04992156
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China
Palbociclib and Cetuximab Versus Cetuximab Monotherapy for Patients With CDKN2A-altered, HPV-unrelated Head and Neck Squamous Cell Carcinoma Who Experienced Disease Progression on a PD-1/L1 Inhibitor
- Conditions
- Interventions
- First Posted Date
- 2021-07-19
- Last Posted Date
- 2024-10-03
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 81
- Registration Number
- NCT04966481
- Locations
- 🇺🇸
Saint Luke's Hospital, Kansas City, Missouri, United States
🇺🇸Washington University School of Medicine, Saint Louis, Missouri, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.